Cargando…
A Review of Time Courses and Predictors of Lipid Changes with Fenofibric Acid-Statin Combination
Fibrates activate peroxisome proliferator activated receptor α and exert beneficial effects on triglycerides, high-density lipoprotein cholesterol, and low density lipoprotein subspecies. Fenofibric acid (FA) has been studied in a large number of patients with mixed dyslipidemia, combined with a low...
Autor principal: | Filippatos, Theodosios D. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3368211/ https://www.ncbi.nlm.nih.gov/pubmed/22592524 http://dx.doi.org/10.1007/s10557-012-6394-0 |
Ejemplares similares
-
Management of dyslipidemias with fibrates, alone and in combination with statins: role of delayed-release fenofibric acid
por: Moutzouri, Elisavet, et al.
Publicado: (2010) -
Fenofibric acid: a new fibrate approved for use in combination with statin for the treatment of mixed dyslipidemia
por: Alagona, Peter
Publicado: (2010) -
A Review of Currently Available Fenofibrate and Fenofibric Acid Formulations
por: Ling, Hua, et al.
Publicado: (2013) -
A review on the rationale and clinical use of concomitant rosuvastatin and fenofibrate/fenofibric acid therapy
por: Strain, Joe D, et al.
Publicado: (2010) -
Cost-Effectiveness of Icosapent Ethyl, Evolocumab, Alirocumab, Ezetimibe, or Fenofibrate in Combination with Statins Compared to Statin Monotherapy
por: Michaeli, Daniel Tobias, et al.
Publicado: (2022)